EGFR and non-small cell lung carcinoma: The phases I and II Iressa NSCLC Trial Assessing Combination Treatment (INTACT) study, which focused on EGFR mutation‐unknown NSCLC did not demonstrate a benefit in the survival or response to combination therapy.